Matches in Nanopublications for { ?s ?p "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP653330.RACx3nfBtD5lcxo_6RmJaKflraz8RNI1isePt2PZDICOo130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP653330.RACx3nfBtD5lcxo_6RmJaKflraz8RNI1isePt2PZDICOo130_provenance.
- NP626366.RAWa_MsxvOBeeIuLc6UPCC5adGor3yZhOe1DhxbpAfX28130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP626366.RAWa_MsxvOBeeIuLc6UPCC5adGor3yZhOe1DhxbpAfX28130_provenance.
- NP891477.RARgDVd3jwf72Df43fCS7XBbqU1vJGPImO1FpezwPFnK0130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP891477.RARgDVd3jwf72Df43fCS7XBbqU1vJGPImO1FpezwPFnK0130_provenance.
- NP888589.RAjgDP1X3xCZRGWuZ4dafxARGb8cZrHW2tXMrfMxFhDUs130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP888589.RAjgDP1X3xCZRGWuZ4dafxARGb8cZrHW2tXMrfMxFhDUs130_provenance.
- NP443353.RAmsL1DNaM3OsgwuaVKKbj4VS0uuHIrqlJRykr1-bCkM8130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP443353.RAmsL1DNaM3OsgwuaVKKbj4VS0uuHIrqlJRykr1-bCkM8130_provenance.
- NP521039.RAX5v-01YR40otoIFNAHVuaYTgFhg683xcSIIG9TB0HgI130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521039.RAX5v-01YR40otoIFNAHVuaYTgFhg683xcSIIG9TB0HgI130_provenance.
- NP305822.RAJjbbjVjlUJxlg17xs1Hom7zNAtEySnFfGelGxMSopjU130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP305822.RAJjbbjVjlUJxlg17xs1Hom7zNAtEySnFfGelGxMSopjU130_provenance.
- NP190676.RA2JiqyDlipjbeGOJGWPUeRoTayTTaYBX6PgWLwwaoNJg130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP190676.RA2JiqyDlipjbeGOJGWPUeRoTayTTaYBX6PgWLwwaoNJg130_provenance.
- NP914861.RA-Zixv6ke_yfp4mcjDAhXyx8CrHLEagiCAmNQKf5BE7A130_assertion description "[Our data indicate that CD4+ immune responses against CEA develop in neoplastic patients, suggesting that tolerance toward CEA or cross-reactive CD66 homologous molecules might be either not absolute or be overcome in the neoplastic disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914861.RA-Zixv6ke_yfp4mcjDAhXyx8CrHLEagiCAmNQKf5BE7A130_provenance.